CHRS

Coherus Oncology Stock Analysis

AI Rating

Good
  • Quality0/10
  • Growth↑ 9/10
  • Value↑ 8/10
Coherus Oncology sales and earnings growth
CHRS Growth
Great
  • Revenue Y/Y↑ 59.81%
  • EPS Y/Y↑ 472.00%
  • FCF Y/Y↓ -577.66%
Coherus Oncology gross and profit margin trends
CHRS Profitability
Great
  • Gross margin ↑ 67.20%
  • EPS margin↑ 398.40%
  • ROIC 5Y↑ 30.59%
Coherus Oncology net debt vs free cash flow
CHRS Risk
Great
  • Debt / Equity↓ 0.6
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 19.7

Coherus Oncology stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗